Presentation is loading. Please wait.

Presentation is loading. Please wait.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of Low-Dose Human Atrial Natriuretic Peptide.

Similar presentations


Presentation on theme: "Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of Low-Dose Human Atrial Natriuretic Peptide."— Presentation transcript:

1 Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of Low-Dose Human Atrial Natriuretic Peptide Infusion in Nondialysis Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting: The NU-HIT (Nihon University Working Group Study of Low-Dose hANP Infusion Therapy During Cardiac Surgery) Trial for CKD J Am Coll Cardiol. 2011;58(9):897-903. doi:10.1016/j.jacc.2011.03.056 Study Population A total of 303 patients registered in the NU-HIT (Nihon University Working Group Study of Low-Dose hANP Infusion Therapy During Cardiac Surgery) trial for chronic kidney disease (CKD) were randomly assigned to receive human atrial natriuretic peptide (hANP) therapy (hANP group) or placebo therapy (placebo group). Figure Legend:

2 Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of Low-Dose Human Atrial Natriuretic Peptide Infusion in Nondialysis Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting: The NU-HIT (Nihon University Working Group Study of Low-Dose hANP Infusion Therapy During Cardiac Surgery) Trial for CKD J Am Coll Cardiol. 2011;58(9):897-903. doi:10.1016/j.jacc.2011.03.056 Dialysis-Free Rate The dialysis-free rate was significantly higher in the human atrial natriuretic peptide (hANP) group (solid line) than in the placebo group (dashed line). Figure Legend:

3 Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of Low-Dose Human Atrial Natriuretic Peptide Infusion in Nondialysis Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting: The NU-HIT (Nihon University Working Group Study of Low-Dose hANP Infusion Therapy During Cardiac Surgery) Trial for CKD J Am Coll Cardiol. 2011;58(9):897-903. doi:10.1016/j.jacc.2011.03.056 Overall Survival Rate and Cardiac Event-Free Rate (A) The overall survival rate showed no significant difference between the 2 groups. (B) The cardiac event-free rate was significantly higher in the human atrial natriuretic peptide (hANP) group (solid lines) than in the placebo group (dashed lines). Figure Legend:

4 Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of Low-Dose Human Atrial Natriuretic Peptide Infusion in Nondialysis Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting: The NU-HIT (Nihon University Working Group Study of Low-Dose hANP Infusion Therapy During Cardiac Surgery) Trial for CKD J Am Coll Cardiol. 2011;58(9):897-903. doi:10.1016/j.jacc.2011.03.056 Data of Serum Creatinine Increase Rate Creatinine increase was 21.6 ± 42.8% in the human atrial natriuretic peptide (hANP) group and 71.1 ± 130.6% in the placebo group, being significantly higher in the placebo group. Figure Legend:


Download ppt "Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of Low-Dose Human Atrial Natriuretic Peptide."

Similar presentations


Ads by Google